Bicara Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Bicara Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 91% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-242.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 91% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-95.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 82% of Healthcare companies in United States.
Cash Cushion Ratio
+37%Cash, after subtracting all debt, equals 37% of its market value (net cash).
Higher than 71% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Bicara Therapeutics Inc. made a loss over the last year. Bicara Therapeutics Inc. owes $0.08 for every $1 it owns. Bicara Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBicara Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.41The share price is 2.41 times Bicara Therapeutics Inc.'s book value per share, lower than 52% of Healthcare companies in United States.
Market cap
$1.1 BThe total market value of all of Bicara Therapeutics Inc.'s shares at today's price (share price × number of shares), larger than 65% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$469 MWhat Bicara Therapeutics Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$7.08Net worth divided by the number of shares. The share price of $17.07 is 2.4 times this, which is the P/B above.
Return on equity (ROE)
-41.0%Bicara Therapeutics Inc. lost 41.0% of its shareholders' money over the last year, higher than 54% of Healthcare companies in United States.
Owes vs Owns
0.08×Bicara Therapeutics Inc. owes $0.08 for every $1 it owns (low), lower than 89% of Healthcare companies in United States.
Dividend yield
NoneBicara Therapeutics Inc. does not currently pay a dividend.
Profit growth
LossBicara Therapeutics Inc. made a loss in each of the last two years.
Cash vs debt
Net cashBicara Therapeutics Inc. held $413 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Bicara Therapeutics Inc.: $1.1 B ÷ $469 M (30 Jun 2026) = 2.4.
What is Bicara Therapeutics Inc.'s return on equity?
Bicara Therapeutics Inc. lost 41.0% of its shareholders' money over the last year, higher than 54% of Healthcare companies in United States.
How much does Bicara Therapeutics Inc. owe compared with what it owns?
Bicara Therapeutics Inc. owes $0.08 for every $1 it owns (low), lower than 89% of Healthcare companies in United States.
Does Bicara Therapeutics Inc. pay a dividend?
No. Bicara Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.